Drug maker Bristol-Myers Squibb (BMY) reported some promising results in a Phase-I trial for a cancer drug that helps the body fight cancer cells by harnessing the patient’s immune system.
Link to the trial study results: http://seekingalpha.com/news-article/3046321-investigational-anti-pd-1-immunotherapy-bms-936558-showed-clinical-activity-in-phase-1-trial-of-patients-with-previously-treated-non-small-cell-lung-cancer-metastatic-melanoma-and-renal-cell-cancer
Though the sample size was relatively small, the firm’s study showed that the immune system was more responsive while under drug therapy. Nevertheless, this is the first stage of a very long process to approval, and we aren’t too excited about shares at current levels. We prefer Pfizer (PFE) or Teva Pharmaceuticals (TEVA) at current levels on the basis of our Valuentum Buying Index.
Please click the following link to view our reports on the pharmaceutical industry: